J Ethnopharmacol:中药通过抑制NLRP3炎症小体对缺血性脑卒中的调控

2022-06-14 August MedSci原创

许多研究表明,多种中药(TCM) 对 NLRP3 炎性体介导的缺血性脑损伤具有强大的神经保护能力。这些中药可以是中药方剂、中药材及其提取物、中药单体等形式。

中风是一个重要的全球公共卫生问题,发病率、死亡率和残疾率都很高。大约 75-80% 的中风被归类为缺血性中风 (IS)。在中国,IS 是成人死亡的主要原因。IS 每年新增病例超过 200 万例,给社会和经济造成巨大负担。炎症诱导的神经元死亡是 IS 中的一个关键事件。在这个过程中,缺血和缺氧触发了常驻炎症细胞(星形胶质细胞、小胶质细胞和内皮细胞)的快速激活和脑内细胞间核因子的易位,以促进促炎因子的成熟和释放

核苷酸结合寡聚化结构域样受体 (NLR) 在称为炎性体的多蛋白平台的组装中起主要作用。在 NLR 中,NLRP3 是 NLR 家族的一个亚型。NLRP3炎症小体导致活化的caspase-1产生大量炎症因子,引起神经炎症,参与IS的发生发展。靶向抑制 NLRP3 炎症小体的激活可以缓解炎症反应,促进神经细胞存活,达到神经保护作用。因此,为提高IS患者的功能恢复,迫切需要开发新的治疗靶点和有效药物。

中医药在 IS 的治疗中逐渐得到了系统的研究和应用。由于中医药的多靶点、多环节、多系统、多途径作用,在治疗包括IS在内的多种疾病方面具有独特优势。此外,中药对 IS 的治疗作用与 NLPR3 炎性体的调节密切相关,表明它们有可能成为一种新的 IS 治疗策略。

材料和方法:通过设置关键词“NLRP3炎症小体”和“中药”以及“缺血性中风”来回顾最近发表的文章;Pubmed 和 GeenMedical 中的“NLRP3 炎症小体”和“缺血性中风”以及“天然产物”等。结果:根据最近的研究,16个中药方剂(官方授权产品和临床有效中药方剂)、7种中草药提取物和29种中药单体通过抗炎、抗氧化应激、抗凋亡和抗氧化应激对IS具有保护作用。线粒体自噬作用。

综上所述,此综述对针对 NLRP3 治疗 IS 的处方、草药提取物和中药活性单体成分的应用文献进行了系统回顾。证明了 NLRP3 炎性体是缓解 IS 的关键靶点,为进一步应用中医药治疗IS提供参考。

 

原文:Tao YW, Yang L, Chen SY, Zhang Y, Zeng Y, Wu JS, Meng XL. Pivotal regulatory roles of traditional Chinese medicine in ischemic stroke via inhibition of NLRP3 inflammasome. J Ethnopharmacol. 2022 May 2;294:115316. doi: 10.1016/j.jep.2022.115316. Epub ahead of print. PMID: 35513214.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1996486, encodeId=6242199648695, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Oct 28 11:04:17 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908715, encodeId=6c8f1908e150f, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Dec 13 11:04:17 CST 2022, time=2022-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788481, encodeId=af571e884814a, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Mar 04 22:04:17 CST 2023, time=2023-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807178, encodeId=f927180e17826, content=<a href='/topic/show?id=245de9378aa' target=_blank style='color:#2F92EE;'>#缺血性脑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79378, encryptionId=245de9378aa, topicName=缺血性脑)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Sat Sep 17 12:04:17 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787803, encodeId=ff891e87803e2, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Apr 24 17:04:17 CST 2023, time=2023-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690694, encodeId=9d62169069485, content=<a href='/topic/show?id=f684128e260' target=_blank style='color:#2F92EE;'>#NLRP3炎症小体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12872, encryptionId=f684128e260, topicName=NLRP3炎症小体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=720529078091, createdName=bluefate131, createdTime=Sun Jun 12 21:04:17 CST 2022, time=2022-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893514, encodeId=d545189351472, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Nov 16 22:04:17 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226412, encodeId=d3d81226412d4, content=学习一下NLRP3炎症小体, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50ab8125206, createdName=yvaine, createdTime=Tue Jun 14 16:08:34 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226343, encodeId=37361226343c2, content=签到学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Tue Jun 14 09:57:16 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407776, encodeId=af63140e7763a, content=<a href='/topic/show?id=a22412862b3' target=_blank style='color:#2F92EE;'>#NLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12862, encryptionId=a22412862b3, topicName=NLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd32710930, createdName=yuandd, createdTime=Wed Jun 01 14:04:17 CST 2022, time=2022-06-01, status=1, ipAttribution=)]
    2022-10-28 yb6560
  2. [GetPortalCommentsPageByObjectIdResponse(id=1996486, encodeId=6242199648695, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Oct 28 11:04:17 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908715, encodeId=6c8f1908e150f, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Dec 13 11:04:17 CST 2022, time=2022-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788481, encodeId=af571e884814a, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Mar 04 22:04:17 CST 2023, time=2023-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807178, encodeId=f927180e17826, content=<a href='/topic/show?id=245de9378aa' target=_blank style='color:#2F92EE;'>#缺血性脑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79378, encryptionId=245de9378aa, topicName=缺血性脑)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Sat Sep 17 12:04:17 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787803, encodeId=ff891e87803e2, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Apr 24 17:04:17 CST 2023, time=2023-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690694, encodeId=9d62169069485, content=<a href='/topic/show?id=f684128e260' target=_blank style='color:#2F92EE;'>#NLRP3炎症小体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12872, encryptionId=f684128e260, topicName=NLRP3炎症小体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=720529078091, createdName=bluefate131, createdTime=Sun Jun 12 21:04:17 CST 2022, time=2022-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893514, encodeId=d545189351472, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Nov 16 22:04:17 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226412, encodeId=d3d81226412d4, content=学习一下NLRP3炎症小体, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50ab8125206, createdName=yvaine, createdTime=Tue Jun 14 16:08:34 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226343, encodeId=37361226343c2, content=签到学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Tue Jun 14 09:57:16 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407776, encodeId=af63140e7763a, content=<a href='/topic/show?id=a22412862b3' target=_blank style='color:#2F92EE;'>#NLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12862, encryptionId=a22412862b3, topicName=NLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd32710930, createdName=yuandd, createdTime=Wed Jun 01 14:04:17 CST 2022, time=2022-06-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1996486, encodeId=6242199648695, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Oct 28 11:04:17 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908715, encodeId=6c8f1908e150f, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Dec 13 11:04:17 CST 2022, time=2022-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788481, encodeId=af571e884814a, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Mar 04 22:04:17 CST 2023, time=2023-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807178, encodeId=f927180e17826, content=<a href='/topic/show?id=245de9378aa' target=_blank style='color:#2F92EE;'>#缺血性脑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79378, encryptionId=245de9378aa, topicName=缺血性脑)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Sat Sep 17 12:04:17 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787803, encodeId=ff891e87803e2, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Apr 24 17:04:17 CST 2023, time=2023-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690694, encodeId=9d62169069485, content=<a href='/topic/show?id=f684128e260' target=_blank style='color:#2F92EE;'>#NLRP3炎症小体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12872, encryptionId=f684128e260, topicName=NLRP3炎症小体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=720529078091, createdName=bluefate131, createdTime=Sun Jun 12 21:04:17 CST 2022, time=2022-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893514, encodeId=d545189351472, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Nov 16 22:04:17 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226412, encodeId=d3d81226412d4, content=学习一下NLRP3炎症小体, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50ab8125206, createdName=yvaine, createdTime=Tue Jun 14 16:08:34 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226343, encodeId=37361226343c2, content=签到学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Tue Jun 14 09:57:16 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407776, encodeId=af63140e7763a, content=<a href='/topic/show?id=a22412862b3' target=_blank style='color:#2F92EE;'>#NLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12862, encryptionId=a22412862b3, topicName=NLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd32710930, createdName=yuandd, createdTime=Wed Jun 01 14:04:17 CST 2022, time=2022-06-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1996486, encodeId=6242199648695, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Oct 28 11:04:17 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908715, encodeId=6c8f1908e150f, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Dec 13 11:04:17 CST 2022, time=2022-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788481, encodeId=af571e884814a, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Mar 04 22:04:17 CST 2023, time=2023-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807178, encodeId=f927180e17826, content=<a href='/topic/show?id=245de9378aa' target=_blank style='color:#2F92EE;'>#缺血性脑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79378, encryptionId=245de9378aa, topicName=缺血性脑)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Sat Sep 17 12:04:17 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787803, encodeId=ff891e87803e2, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Apr 24 17:04:17 CST 2023, time=2023-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690694, encodeId=9d62169069485, content=<a href='/topic/show?id=f684128e260' target=_blank style='color:#2F92EE;'>#NLRP3炎症小体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12872, encryptionId=f684128e260, topicName=NLRP3炎症小体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=720529078091, createdName=bluefate131, createdTime=Sun Jun 12 21:04:17 CST 2022, time=2022-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893514, encodeId=d545189351472, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Nov 16 22:04:17 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226412, encodeId=d3d81226412d4, content=学习一下NLRP3炎症小体, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50ab8125206, createdName=yvaine, createdTime=Tue Jun 14 16:08:34 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226343, encodeId=37361226343c2, content=签到学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Tue Jun 14 09:57:16 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407776, encodeId=af63140e7763a, content=<a href='/topic/show?id=a22412862b3' target=_blank style='color:#2F92EE;'>#NLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12862, encryptionId=a22412862b3, topicName=NLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd32710930, createdName=yuandd, createdTime=Wed Jun 01 14:04:17 CST 2022, time=2022-06-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1996486, encodeId=6242199648695, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Oct 28 11:04:17 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908715, encodeId=6c8f1908e150f, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Dec 13 11:04:17 CST 2022, time=2022-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788481, encodeId=af571e884814a, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Mar 04 22:04:17 CST 2023, time=2023-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807178, encodeId=f927180e17826, content=<a href='/topic/show?id=245de9378aa' target=_blank style='color:#2F92EE;'>#缺血性脑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79378, encryptionId=245de9378aa, topicName=缺血性脑)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Sat Sep 17 12:04:17 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787803, encodeId=ff891e87803e2, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Apr 24 17:04:17 CST 2023, time=2023-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690694, encodeId=9d62169069485, content=<a href='/topic/show?id=f684128e260' target=_blank style='color:#2F92EE;'>#NLRP3炎症小体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12872, encryptionId=f684128e260, topicName=NLRP3炎症小体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=720529078091, createdName=bluefate131, createdTime=Sun Jun 12 21:04:17 CST 2022, time=2022-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893514, encodeId=d545189351472, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Nov 16 22:04:17 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226412, encodeId=d3d81226412d4, content=学习一下NLRP3炎症小体, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50ab8125206, createdName=yvaine, createdTime=Tue Jun 14 16:08:34 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226343, encodeId=37361226343c2, content=签到学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Tue Jun 14 09:57:16 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407776, encodeId=af63140e7763a, content=<a href='/topic/show?id=a22412862b3' target=_blank style='color:#2F92EE;'>#NLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12862, encryptionId=a22412862b3, topicName=NLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd32710930, createdName=yuandd, createdTime=Wed Jun 01 14:04:17 CST 2022, time=2022-06-01, status=1, ipAttribution=)]
    2023-04-24 jj000001
  6. [GetPortalCommentsPageByObjectIdResponse(id=1996486, encodeId=6242199648695, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Oct 28 11:04:17 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908715, encodeId=6c8f1908e150f, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Dec 13 11:04:17 CST 2022, time=2022-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788481, encodeId=af571e884814a, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Mar 04 22:04:17 CST 2023, time=2023-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807178, encodeId=f927180e17826, content=<a href='/topic/show?id=245de9378aa' target=_blank style='color:#2F92EE;'>#缺血性脑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79378, encryptionId=245de9378aa, topicName=缺血性脑)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Sat Sep 17 12:04:17 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787803, encodeId=ff891e87803e2, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Apr 24 17:04:17 CST 2023, time=2023-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690694, encodeId=9d62169069485, content=<a href='/topic/show?id=f684128e260' target=_blank style='color:#2F92EE;'>#NLRP3炎症小体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12872, encryptionId=f684128e260, topicName=NLRP3炎症小体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=720529078091, createdName=bluefate131, createdTime=Sun Jun 12 21:04:17 CST 2022, time=2022-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893514, encodeId=d545189351472, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Nov 16 22:04:17 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226412, encodeId=d3d81226412d4, content=学习一下NLRP3炎症小体, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50ab8125206, createdName=yvaine, createdTime=Tue Jun 14 16:08:34 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226343, encodeId=37361226343c2, content=签到学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Tue Jun 14 09:57:16 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407776, encodeId=af63140e7763a, content=<a href='/topic/show?id=a22412862b3' target=_blank style='color:#2F92EE;'>#NLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12862, encryptionId=a22412862b3, topicName=NLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd32710930, createdName=yuandd, createdTime=Wed Jun 01 14:04:17 CST 2022, time=2022-06-01, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1996486, encodeId=6242199648695, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Oct 28 11:04:17 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908715, encodeId=6c8f1908e150f, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Dec 13 11:04:17 CST 2022, time=2022-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788481, encodeId=af571e884814a, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Mar 04 22:04:17 CST 2023, time=2023-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807178, encodeId=f927180e17826, content=<a href='/topic/show?id=245de9378aa' target=_blank style='color:#2F92EE;'>#缺血性脑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79378, encryptionId=245de9378aa, topicName=缺血性脑)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Sat Sep 17 12:04:17 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787803, encodeId=ff891e87803e2, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Apr 24 17:04:17 CST 2023, time=2023-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690694, encodeId=9d62169069485, content=<a href='/topic/show?id=f684128e260' target=_blank style='color:#2F92EE;'>#NLRP3炎症小体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12872, encryptionId=f684128e260, topicName=NLRP3炎症小体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=720529078091, createdName=bluefate131, createdTime=Sun Jun 12 21:04:17 CST 2022, time=2022-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893514, encodeId=d545189351472, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Nov 16 22:04:17 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226412, encodeId=d3d81226412d4, content=学习一下NLRP3炎症小体, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50ab8125206, createdName=yvaine, createdTime=Tue Jun 14 16:08:34 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226343, encodeId=37361226343c2, content=签到学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Tue Jun 14 09:57:16 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407776, encodeId=af63140e7763a, content=<a href='/topic/show?id=a22412862b3' target=_blank style='color:#2F92EE;'>#NLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12862, encryptionId=a22412862b3, topicName=NLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd32710930, createdName=yuandd, createdTime=Wed Jun 01 14:04:17 CST 2022, time=2022-06-01, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1996486, encodeId=6242199648695, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Oct 28 11:04:17 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908715, encodeId=6c8f1908e150f, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Dec 13 11:04:17 CST 2022, time=2022-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788481, encodeId=af571e884814a, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Mar 04 22:04:17 CST 2023, time=2023-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807178, encodeId=f927180e17826, content=<a href='/topic/show?id=245de9378aa' target=_blank style='color:#2F92EE;'>#缺血性脑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79378, encryptionId=245de9378aa, topicName=缺血性脑)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Sat Sep 17 12:04:17 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787803, encodeId=ff891e87803e2, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Apr 24 17:04:17 CST 2023, time=2023-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690694, encodeId=9d62169069485, content=<a href='/topic/show?id=f684128e260' target=_blank style='color:#2F92EE;'>#NLRP3炎症小体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12872, encryptionId=f684128e260, topicName=NLRP3炎症小体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=720529078091, createdName=bluefate131, createdTime=Sun Jun 12 21:04:17 CST 2022, time=2022-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893514, encodeId=d545189351472, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Nov 16 22:04:17 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226412, encodeId=d3d81226412d4, content=学习一下NLRP3炎症小体, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50ab8125206, createdName=yvaine, createdTime=Tue Jun 14 16:08:34 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226343, encodeId=37361226343c2, content=签到学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Tue Jun 14 09:57:16 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407776, encodeId=af63140e7763a, content=<a href='/topic/show?id=a22412862b3' target=_blank style='color:#2F92EE;'>#NLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12862, encryptionId=a22412862b3, topicName=NLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd32710930, createdName=yuandd, createdTime=Wed Jun 01 14:04:17 CST 2022, time=2022-06-01, status=1, ipAttribution=)]
    2022-06-14 yvaine

    学习一下NLRP3炎症小体

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1996486, encodeId=6242199648695, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Oct 28 11:04:17 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908715, encodeId=6c8f1908e150f, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Dec 13 11:04:17 CST 2022, time=2022-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788481, encodeId=af571e884814a, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Mar 04 22:04:17 CST 2023, time=2023-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807178, encodeId=f927180e17826, content=<a href='/topic/show?id=245de9378aa' target=_blank style='color:#2F92EE;'>#缺血性脑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79378, encryptionId=245de9378aa, topicName=缺血性脑)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Sat Sep 17 12:04:17 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787803, encodeId=ff891e87803e2, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Apr 24 17:04:17 CST 2023, time=2023-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690694, encodeId=9d62169069485, content=<a href='/topic/show?id=f684128e260' target=_blank style='color:#2F92EE;'>#NLRP3炎症小体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12872, encryptionId=f684128e260, topicName=NLRP3炎症小体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=720529078091, createdName=bluefate131, createdTime=Sun Jun 12 21:04:17 CST 2022, time=2022-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893514, encodeId=d545189351472, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Nov 16 22:04:17 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226412, encodeId=d3d81226412d4, content=学习一下NLRP3炎症小体, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50ab8125206, createdName=yvaine, createdTime=Tue Jun 14 16:08:34 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226343, encodeId=37361226343c2, content=签到学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Tue Jun 14 09:57:16 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407776, encodeId=af63140e7763a, content=<a href='/topic/show?id=a22412862b3' target=_blank style='color:#2F92EE;'>#NLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12862, encryptionId=a22412862b3, topicName=NLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd32710930, createdName=yuandd, createdTime=Wed Jun 01 14:04:17 CST 2022, time=2022-06-01, status=1, ipAttribution=)]
    2022-06-14 屋顶瞄爱赏月

    签到学习

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1996486, encodeId=6242199648695, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Oct 28 11:04:17 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908715, encodeId=6c8f1908e150f, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Dec 13 11:04:17 CST 2022, time=2022-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788481, encodeId=af571e884814a, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Mar 04 22:04:17 CST 2023, time=2023-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807178, encodeId=f927180e17826, content=<a href='/topic/show?id=245de9378aa' target=_blank style='color:#2F92EE;'>#缺血性脑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79378, encryptionId=245de9378aa, topicName=缺血性脑)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Sat Sep 17 12:04:17 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787803, encodeId=ff891e87803e2, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Apr 24 17:04:17 CST 2023, time=2023-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690694, encodeId=9d62169069485, content=<a href='/topic/show?id=f684128e260' target=_blank style='color:#2F92EE;'>#NLRP3炎症小体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12872, encryptionId=f684128e260, topicName=NLRP3炎症小体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=720529078091, createdName=bluefate131, createdTime=Sun Jun 12 21:04:17 CST 2022, time=2022-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893514, encodeId=d545189351472, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Nov 16 22:04:17 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226412, encodeId=d3d81226412d4, content=学习一下NLRP3炎症小体, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50ab8125206, createdName=yvaine, createdTime=Tue Jun 14 16:08:34 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226343, encodeId=37361226343c2, content=签到学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Tue Jun 14 09:57:16 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407776, encodeId=af63140e7763a, content=<a href='/topic/show?id=a22412862b3' target=_blank style='color:#2F92EE;'>#NLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12862, encryptionId=a22412862b3, topicName=NLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd32710930, createdName=yuandd, createdTime=Wed Jun 01 14:04:17 CST 2022, time=2022-06-01, status=1, ipAttribution=)]
    2022-06-01 yuandd

相关资讯

Front Pharmacol:中药复方丹参白疕消对咪喹莫特所致小鼠银屑病样炎症的改善作用

评估丹参白疕消的抗银屑病作用,并探讨其在咪喹莫特诱导的银屑病样小鼠模型中的潜在机制。

Blood:在成人T细胞白血病/淋巴瘤中,IRF4和NF-κB形成一个前馈回路调控基因表达

中心点:在ATL细胞,IRF4和NF-κB形成一个前馈回路,协同调控基因的表达。IRF4和NF-κB结合在超级增强子丰富区域,调控重要致癌基因表达,包括MYC、CCR4和BIRC3。摘要:成人T细胞白血病/淋巴瘤(ATL)是一种来源于成熟CD4+T淋巴细胞的高侵袭性的恶性血液病。近期,研究人员发现,ATL细胞转录调控网络由两个致癌转录因子(IRF4和NF-κB)驱动。原发性ATL样本的基因表达谱显

Diabetologia:糖尿病合并主动脉狭窄与NF-κB表达增加以及更明显的瓣膜钙化有关

主动脉瓣狭窄(AS)是一种进行性疾病,与主动脉瓣口减少和由于钙积聚而导致的小叶活动减少有关。

Blood:以NF-κB和Notch为靶点治疗淋巴瘤

近日,《血液》杂志上发表了一篇文章,提供了遗传学证据,表明在B细胞中同时激活NF-κB和Notch信号足以诱导B细胞淋巴瘤转化,并启动普通的祖细胞通过去分化转化成髓系,而非转分化。有趣的是,转化的髓细胞还可以进一步转化为髓细胞白血病,虽然发生频率较低。

Blood:自分泌LTA信号驱动霍奇金淋巴瘤的NF-κB和JAK-STAT活性以及髓系基因的表达

NF-κB的持续性激活是典型霍奇金淋巴瘤(cHL)中的恶性霍奇金/RS(HRS)细胞的标志。基因组损伤、EB病毒感染、可溶性因子和肿瘤微环境的相互作用都可导致激活。Linda von Hoff等人采用一种公正的方法来识别cHL细胞分泌的可激活NF-κB的关键因子,采用色谱和质谱分析培养的cHL细胞的分泌蛋白质组。研究人员明确了α淋巴毒素(LTA)是cHL细胞系的经典和非经典NF-κB信号自分泌和旁

J Endod:抑制NF-κB通路减弱实验性尖周损伤的进展

NF-κB是血管再生的一个重要调控因子,它涉及到B-cell lymphoma 2 (Bcl-2)和Bcl-2-associated X protein (Bax)信号通路。因此,抑制NF-κB可能会通过阻断血管再生减弱尖周损伤的进展。为此,这篇研究的目的是为了评估NF-κB抑制剂寡脱氧核苷酸(ODN)对实验性尖周损伤的影响。